Negative Hormone Receptor and APOcrine Lobular Invasive Breast Cancer

Summary

The NAPOLI Study is a retrospective multicenter observational study designed to characterize negative hormone receptor and apocrine lobular invasive breast cancer. The study will collect real-world clinicopathological, molecular, therapeutic and outcome data from patients diagnosed and treated at participating centers. The aim is to describe the clinical behavior, pathological features, receptor profile, treatments received and oncologic outcomes of this rare breast cancer subtype.

Eligibility

Inclusion Criteria:

* Female or male patients aged ≥18 years.
* Histologically confirmed invasive lobular carcinoma of the breast.
* Presence of apocrine differentiation/features documented in pathology report or confirmed by local pathology review.
* Negative hormone receptors.
* Diagnosis and/or treatment at one of the participating centers.
* Availability of essential clinicopathological data.
* Availability of follow-up data, when applicable.

Exclusion Criteria:

* Pure ductal carcinoma without lobular invasive component.
* Metastatic tumor to the breast from non-breast primary cancer.
* Insufficient pathological documentation to confirm eligibility.
* Missing essential clinical data.
* Patients who denied consent for retrospective data use, where applicable by local regulations.

Conditions3

Interventions1

Related trials

• Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer — Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer — SciClone Pharmaceuticals
• Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer — The First Affiliated Hospital with Nanjing Medical University
• Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients — Region Örebro County
• Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer — GBG Forschungs GmbH
• Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer — Xijing Hospital
• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer — Puma Biotechnology, Inc.
• Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases — H. Lee Moffitt Cancer Center and Research Institute

Browse More Trials